X chromosome inactivation (XCI) transcriptionally silences an X chromosome early in mammalian development, thereby serving as a means of dosage compensation between the sexes (reviewed in [@bib32]). XCI is a classic paradigm of epigenetic silencing, but while many of the molecular players in the inactivation process have been elucidated ([@bib49]), less is known about the *cis*-acting DNA elements involved in the spread of silencing. A substantial number of X-linked genes continue to be expressed from the inactive X (Xi) in humans, and the clustered nature of these escapees in humans suggests that escape from XCI may be regulated in domains ([@bib5]). Intriguingly, the number of escapees in mouse is considerably more limited, with only ∼4% of genes escaping XCI (∼20 transcripts) in mice compared to ∼15% (∼94 transcripts) of analyzed human genes ([@bib5]; [@bib28]; [@bib51]; [@bib41]). The ongoing escape from inactivation of the escapee *Kdm5c* when integrated at four different locations on the mouse X chromosome, while its flanking genes maintain their inactive state, provides strong evidence for intrinsic regulatory sequences, which we refer to as escape elements, that allow genes to escape from XCI ([@bib27]).

[@bib16] proposed the existence of waystations or booster elements that promote the spread of inactivation, based on the limited inactivation of autosomal regions of X;autosome translocations, and Lyon proposed that long interspersed elements (LINEs) that are enriched on the X chromosome could be such waystations ([@bib46]; [@bib35]; [@bib29]). Computational studies comparing the genomic neighborhoods of genes with different inactivation status have supported that inactivated and escape genes have different genomic environments with respect to the content of repetitive sequences ([@bib2]; [@bib6]; [@bib45]; [@bib33]). Several mouse escapees also escape from XCI in humans, and the difference in inactivation of flanking genes has been attributed to the presence or loss of the CTCF boundary element ([@bib14]; [@bib22]). A direct comparison of the inactivation status of sequences integrated into the same genomic location would permit a direct analysis of the impact of *cis*-acting sequences on XCI and potentially identify sequences containing escape elements, waystations, and/or boundary elements.

Most transgenes on the X chromosome are subject to XCI with the only transgenes shown to consistently escape XCI being a chicken transferrin transgene and the mouse *Kdm5c* bacterial artificial chromosome (BAC) transgene ([@bib19], [@bib20]; [@bib27]), although a human collagen and an NF-ĸB--dependent EGFP reporter gene may also at least partially escape from XCI ([@bib48]; [@bib30]). Lack of knowledge of the integration site for the chicken transferrin transgene confounds the identification of *cis*-acting regulatory elements. Targeted single-copy integrations into a single location would provide a consistent resource to examine the spread of XCI into sequences not normally X linked, and *Hprt* has been described as a permissive locus with relatively minimal effect on transgene expression ([@bib4]; [@bib11]). To assess whether a gene is subject to XCI many studies have examined allelic expression in females with nonrandom inactivation (*e.g.*, [@bib5]; [@bib51]); however, an indirect means of assessing XCI is to study DNA methylation, which can be readily examined on banked DNA samples. CpG island promoters of X-linked genes that are subject to XCI on the Xi are typically DNA hypermethylated, while CpG island promoters are unmethylated on the active X (Xa), as on the autosomes ([@bib48]; [@bib7]; [@bib31]; [@bib8]; [@bib53]). Genes and transgenes that escape XCI demonstrate low levels of promoter DNA methylation on both the Xa and the Xi ([@bib21]; [@bib20]), resulting in overall low DNA methylation levels in both males and females, allowing DNA methylation to be used to assess XCI status of genes ([@bib8]; [@bib53]).

Integration of transgenes at a single locus on the X chromosome allows for detailed examination of *cis*-acting DNA elements and we herein report the analysis of 74 human autosomal and X-linked transgenes knocked into the mouse *Hprt* locus that were generated from the Pleiades Promoter Project ([@bib52]; [@bib34]; J.-F. Schmouth and E. M. Simpson, unpublished data), including eight human autosomal BACs of \>195 kb integrated using the HuGX method \[high-throughput human genes on the X chromosome ([@bib36])\]. Overall there was a significant difference in DNA methylation between males and females, and most human promoters integrated into the X chromosome showed DNA hypermethylation in females, suggesting they were subject to XCI. Silencing from the Xi was verified by expression analysis of four BAC-derived transgenes present on the Xi in females that had nonrandom XCI. We identified one transgene that escaped from XCI and demonstrated that different constructs had differential capacity for DNA methylation when on the Xi, suggesting the presence of additional *cis*-acting epigenetic modulators.

Materials and Methods {#s1}
=====================

Pleiades Promoter Project constructs {#s2}
------------------------------------

The Pleiades Promoter Project ([@bib52]; [@bib34]) was an international collaborative effort to develop various human promoters driving specific expression patterns in the mouse brain, eye, and spinal cord. Most of the promoters originated from human autosomal genes, with only two X-linked promoters, *DCX* and *MAOA*, being assessed. All Pleiades strains were made using homologous recombination at the *Hprt^b-m3^* deletion locus on the mouse X chromosome; integration of the Pleiades constructs generated a chimeric *HPRT*/*Hprt* locus containing the human *HPRT* promoter that rescued the deletion ([@bib4]). MiniPromoters (MiniPs) were ≤4 kb in size and were composed of different combinations of small putative regulatory elements (<http://pleiades.org/>). In contrast, MaxiPromoters (MaxiPs) were human BAC-derived constructs that ranged from 100 to 195 kb of human genomic DNA, with a reporter inserted at the start codon of the gene of interest (J.-F. Schmouth and E. M. Simpson, unpublished data). For the MiniP constructs, the reporter *lacZ* or EGFP (or EGFP/cre) is ∼200 bp or 50 bp downstream of the MiniP, respectively. Thirty-seven of 57 target genes contained a promoter CpG island, which was generally truncated in MiniPs compared to the endogenous islands ([Supporting Information](http://www.genetics.org/cgi/data/genetics.112.143743/DC1/1), [Table S1](http://www.genetics.org/cgi/data/genetics.112.143743/DC1/7)). Approval for the generation and breeding of mice carrying the Pleiades constructs was obtained from the University of British Columbia Committee on Animal Care.

Generation of mouse strains {#s3}
---------------------------

The floxed *Xist* strain 129-*Xist^tm2Jae^* \[stock no. 029172-UNC ([@bib10])\] was obtained heterozygous from the Mutant Mouse Regional Resource Center, and the cre-deleter strain FVB/N-Tg(ACTB-cre)2Mrt \[stock no. 003376 ([@bib26])\] was obtained heterozygous from The Jackson Laboratory (JAX). Both strains were maintained by backcrossing to strain 129S1/SvImJ \[stock no. 002448 ([@bib39])\] obtained from JAX. The floxed *Xist* strain was crossed to the cre-deleter strain at backcross generations JAX-plus N2 and N7, respectively, to generate females carrying the *Xist* deletion (129-X*Xist^1lox^*/X). Females with the *Xist* deletion were then crossed to males with the Pleiades construct integrated at the *Hprt* locus (B6-X^MaxiP^/Y) to generate 129B6F1-X*Xist^1lox^*/X^MaxiP^ females. This *Xist* knockout has been shown to render the X chromosome carrying it unable to inactivate ([@bib23]), thus resulting in the MaxiP knock-in X chromosome with an intact *Xist* becoming the Xi. Complete nonrandom XCI was verified by examining the relative expression levels of the B6 and 129 alleles at a single-nucleotide polymorphism of the *Fln* locus (data not shown).

The B6.129S4-*Gt(ROSA)26Sor^tm1Sor^*/J strain \[stock no. 003474 ([@bib40])\] was obtained homozygous from JAX at N5, maintained by backcrossing to strain C57BL/6J (stock no. 000664) obtained from JAX, and then made homozygous again at N10. The allele was introduced into the Pleiades strains at N5--N10 ([@bib34]).

DNA and RNA extraction from tissues {#s4}
-----------------------------------

An ear notch of ∼1 mm in diameter was taken from each mouse postweaning (∼4 weeks old) and digested with 200 µl of mouse homogenization buffer \[50 mM KCL, 10 mM Tris-HCL, pH 8.3, 2 mM MgCl~2~, 0.1 mg/ml gelatin, 0.45% IGEPAL CA-630 (Sigma-Aldrich), 0.45% Tween 20 (Sigma-Aldrich), and 24 µg of Proteinase K (Sigma-Aldrich)\] overnight at 55°. The digested samples were then heat inactivated at 95° for 10 min. DNA and RNA extractions from 50--100 mg of mouse livers and brains were done using TRIzol Reagent (Invitrogen, Carlsbad, CA), according to the manufacturer's protocol.

Expression analysis {#s5}
-------------------

Expression of constructs was assessed by staining of *lacZ* with X-gal as previously described ([@bib34]). *lacZ* staining was performed on a limited number of ear notch samples ([Table S1](http://www.genetics.org/cgi/data/genetics.112.143743/DC1/7) and [Table S2](http://www.genetics.org/cgi/data/genetics.112.143743/DC1/8)) and on the brains of female mice carrying the *Xist* deletion. The images of *lacZ* staining of the mouse brain sections ([Figure 1](#fig1){ref-type="fig"}) were adjusted for brightness and contrast using Photoshop, but all images for the same construct (test and control samples) received the same adjustments. For analysis of transcription, ∼2 µg of RNA extracted from tissues was converted to cDNA with standard reverse transcription conditions, using M-MLV (Invitrogen) at 42° for 2 hr followed by a 5-min incubation at 95°. Quantitative PCR (qPCR) was used to determine relative transcription levels of *PHB*, *HPRT*, and the intergenic region between *PHB* and *HPRT* compared to *Pgk1* in mice carrying the Ple133 construct (*NGFR* BAC), using a StepOnePlus Real-Time PCR System (Applied Biosystems, Darmstadt, Germany), using Maxima Hot Start Taq (Fermentas) and EvaGreen dye (Biotium). Conditions for qPCR were as follows: 95° for 5 min; followed by 40 cycles of 95° for 15 sec, 60° for 30 sec, and 72° for 1 min; and a melt curve stage of 95° for 15 sec, 60° for 1 min, and an increase of 0.3° until 95°. Serial dilutions of genomic DNA from an *NGFR* female (without the *Xist* deletion) were used as the standards to which each sample cDNA was compared, to generate a relative quantity of the *PHB*, *HPRT*, *Pgk1*, and intergenic transcription between *PHB* and *HPRT*. Expression levels were normalized to *Pgk1* expression level, and quantifications were done in triplicate, with any outlier excluded from the analysis. Primer sequences and distances from the assay to the transcription start site are found in [Table S3](http://www.genetics.org/cgi/data/genetics.112.143743/DC1/9).

DNA methylation analysis {#s6}
------------------------

Using the EZ DNA Methylation-Gold Kit or the EZ-96 DNA Methylation-Gold Kit (Zymo Research), 500 ng of DNA obtained from the lysed ear notches and a limited number of liver and brain samples were bisulfite converted, following the manufacturer's instructions. Internal bisulfite conversion controls were included in the pyrosequencing assays to monitor complete conversion of DNA. Each 25-µl pyrosequencing PCR was performed with 1× PCR buffer (QIAGEN, Valencia, CA), 0.2 mM dNTPs, 0.625 unit Hot Start *Taq* DNA polymerase (QIAGEN), 0.25 µM forward primer, 0.25 µM reverse primer, and 12--35 ng bisulfite-converted DNA. Assays for *CCKBR*, *ICMT*, *NOV*, and *NR2E1* were performed with 0.5 µM forward and reverse primers. Conditions for PCR were 95° for 15 min, 50 cycles of 94° for 30 sec, annealing temperature for 30 sec (see [Table S3](http://www.genetics.org/cgi/data/genetics.112.143743/DC1/9)), 72° for 1 min, and finally 72° for 10 min. One forward or reverse primer was biotinylated, depending on which strand contained the target region to be sequenced, to subsequently isolate the strand of interest for pyrosequencing. Template preparation for pyrosequencing was done according to the manufacturer's protocol, using 10--15 µl of PCR products. CDT tips were used to dispense the nucleotides for pyrosequencing, using the PyroMark MD machine (QIAGEN).

Variability in pyrosequencing results within a sample was observed for some DNA, which we attributed to degradation of ear notch DNA that was stored at 4° for up to 3 years. All promoter assays were replicated at least twice and the average is presented. If the standard deviation of a sample for a particular assay was large enough to be considered an outlier using the modified *Z*-score method (see below), the data point was not included in the analyses. *HPRT*, *Phf6*, and *lacZ* assays were replicated on sufficient samples that we were confident of their reliability (average standard deviations of 5%, 3%, and 5%, respectively), and therefore for these three assays not all samples were replicated. Each human promoter assay was tested in at least one mouse sample without the target transgene to ensure the specificity of the human primers.

The University of California, Santa Cruz (UCSC) definition and designation of a CpG island (GC content of at least 50%, length \>200 bp, observed~CpG~/expected~CpG~ ratio \>0.6) were used ([@bib15]). The promoter of *PHB* was classified as a CpG island with intermediate CpG density, which was defined as having a GC content \>50%, an observed~CpG~/expected~CpG~ \>0.48, length at least 200 bp, and no overlap with the UCSC CpG islands ([@bib47]); the *PHB* promoter CpG island was located using the CpGIE program ([@bib44]). Primers were designed using PSQ Assay Design software (QIAGEN). At least three CpGs were analyzed for each CpG island examined, and the distance of the analyzed CpGs from the transcription start sites can be found in [Table S3](http://www.genetics.org/cgi/data/genetics.112.143743/DC1/9).

Promoter identification of *PITX2* (Ple158) was based on the ENCODE chromatin states track downloaded from the UCSC genome browser ([@bib13]). Repeat masker (<http://www.repeatmasker.org>, Institute for Systems Biology) and Galaxy ([@bib17]; [@bib3]; [@bib18]) were used to determine the base pair composition of LINEs and Alu in the MaxiP constructs.

Statistical analysis {#s7}
--------------------

Statistical analyses were performed using GraphPad Prism 5.02. An α-value of 0.05 was used for testing significance. A Mann--Whitney *t*-test was used to test for significant differences in DNA methylation levels between male and female mice. Mouse strains with modified *Z*-scores \>3.5 in absolute value were considered outliers ([@bib25]). Spearman's correlation was performed to examine the relationship between DNA methylation levels of neighboring genes.

Results {#s8}
=======

DNA methylation reflects XCI of Pleiades constructs {#s9}
---------------------------------------------------

The Pleiades Promoter Project generated reporter constructs with human promoters and targeted them to the *Hprt* locus on the mouse X chromosome by homologous recombination ([@bib52]; [@bib34]; J.-F. Schmouth and E. M. Simpson, unpublished data). Integration of the Pleiades promoter constructs created a chimeric *HPRT*/*Hprt* locus that consisted of the human *HPRT* promoter and exon 1 and mouse *Hprt* exons 2--9 ([Figure 1A](#fig1){ref-type="fig"}). While MiniP constructs contained a human promoter of ≤4 kb in size that drives a reporter (*lacZ*, EGFP, or EGFP/cre), MaxiP constructs were derived from human BACs of up to 195 kb with the reporter (*lacZ* or EGFP) inserted at the translation start codon of the gene of interest on the human BAC. To predict whether the constructs were subject to the *cis*-regulation of XCI now that they were X linked, we generated female mice carrying a deletion at the *Xist* gene \[*Xist^1lox^* ([@bib10])\] on the X chromosome without the knock-in, thereby causing the Pleiades knock-in to always be on the Xi. The MaxiP constructs *AMOTL1* (Ple5), *MAOA* (Ple127), *NR2E1* (Ple142), and *NR2F2* (Ple143) were not expressed in the brains of females heterozygous for the *Xist* deletion, but were expressed in various parts of the brain in females without the *Xist* deletion ([Figure 1B](#fig1){ref-type="fig"}), indicating that these MaxiP constructs are expressed only when present on the Xa and are thus subject to XCI. DNA methylation analysis on DNA from ear notch samples of hemizygous male and heterozygous female mice transgenic for *AMOTL1* and *NR2E1* showed that CpG island promoters on the BACs were significantly DNA hypermethylated in females compared to males of the same strain (*P* \< 0.05; [Figure 1C](#fig1){ref-type="fig"}), in agreement with the XCI statuses assessed by *lacZ* expression in the females with nonrandom XCI. DNA methylation was also examined in brain and/or liver samples for a few constructs, including the *NR2E1* BAC, and similar levels of DNA methylation to those in ear notches were observed ([Table S2](http://www.genetics.org/cgi/data/genetics.112.143743/DC1/8)). We conclude that DNA methylation at CpG island promoters is a reliable predictor of XCI status for transgenes at *Hprt*. DNA methylation was therefore used to determine the XCI status of the remaining MaxiP constructs (*NOV*, *NGFR*, *PITX2*, and *LCT*). *PITX2* (CpG island 46 designation on UCSC) showed less female DNA methylation than the other MaxiP constructs, which could reflect either the presence or the absence of *cis*-acting regulators of XCI or a tendency to be preferentially located on the Xa. To examine the latter possibility we looked at DNA methylation of the flanking *Phf6* and *HPRT* promoters.

![BAC-derived MaxiP constructs of 120--195 kb are subject to XCI and show DNA hypermethylation of CpG island promoters in females compared to males. (A) Experimental system in which human promoters driving a reporter (Pleiades constructs) were integrated at the *Hprt* locus on the mouse X chromosome, using homologous recombination. A chimeric *HPRT*/*Hprt* locus was generated, consisting of the human *HPRT* promoter and first exon and the mouse counterpart for the rest of the gene. The majority of the female mice examined were heterozygous for the human knock-in, so the wild-type (WT) mouse locus is shown below the knock-in chromosome. The sizes of the Pleiades construct and the internal exons are not shown to scale. (B) Generation of mice carrying the Pleiades knock-in on the Xi. Top, the breeding scheme crossing *Xist^1lox^* females with males carrying the Pleiades knock-in, to generate females carrying the *Xist* deletion and the knock-in on the Xi (Xi), and females with wild-type *Xist* and the knock-in, which could be on the Xa or Xi (Xa/Xi). Bottom, the *lacZ* staining in the brains of females with *AMOTL1*, *NR2E1*, *MAOA*, and *NR2F2*. Regions with *lacZ* staining in the brain sections of mice carrying the *NR2E1* transgene are indicated by the white arrowheads. Images labeled with the same tEMS number were obtained from the same mouse. (C) DNA hypermethylation of the MaxiP constructs predicts XCI status. Each construct is denoted with a Pleiades (Ple) number, along with the human gene from which the constructs originate. Constructs with *lacZ* and EGFP as the reporter are colored in blue and green, respectively. DNA methylation of *PITX2* was examined at CpG island 46 (UCSC). The DNA methylation shown for the *LCT* BAC (Ple126) is the promoter DNA methylation at the *MCM6* gene present on the same MaxiP, not at the promoter of the *LCT* gene itself. Significance was tested using a Mann--Whitney *t*-test. n.t., not tested due to the limited sample numbers. Circles, DNA methylation of the individual sample; bar in the center of the error bars, average DNA methylation for the strain; error bars, ±1 standard deviation between mice for the strain; shaded regions, 2 standard deviations from the average DNA methylation level.](1281fig1){#fig1}

DNA methylation of flanking genes reflects both skewing of XCI and differential capacity for DNA methylation on the Xi {#s10}
----------------------------------------------------------------------------------------------------------------------

The Pleiades construct and the human *HPRT* promoter are located on the same chromosome; therefore, if substantial skewing of XCI were present, their DNA methylation levels would be correlated, reflecting the proportion of cells in which they are both on the Xi. In contrast, *Phf6* DNA methylation should not be affected by skewing since it is present on both X chromosomes. The *HPRT* promoter CpG island was truncated in the chimeric gene, but the chimeric gene complemented the *Hprt* deletion and provided resistance to HAT selection. Both the *HPRT* and the *Phf6* promoters demonstrated significant DNA hypermethylation in females compared to males (*HPRT*, female average 38%, male average 5%, *P* \< 0.0001; *Phf6*, female average 34%, male average 5%, *P* \< 0.0001), suggesting that both neighboring genes were generally subject to XCI. Compared to *Phf6* DNA methylation, *HPRT* showed higher variability in promoter DNA methylation levels between female mice (standard deviations: 10% for *HPRT*, 4% for *Phf6*), consistent with variability in levels of skewing of XCI in the samples analyzed. A correlation between the DNA methylation levels at the human promoter and at *HPRT*, but not with *Phf6* was observed ([Figure 2](#fig2){ref-type="fig"}), supporting the presence of skewing of XCI in the analyzed ear notch samples. Intriguingly, different MaxiP constructs showed different slopes in the correlation of their DNA methylation level with *HPRT* ([Figure 2B](#fig2){ref-type="fig"}), suggesting that Pleiades promoters have different capacities for DNA methylation when located at the same site on the Xi. To confirm that different constructs had different levels of DNA methylation on the Xi, we analyzed the promoter and *HPRT* DNA methylation levels in females homozygous for the knock-in and in females heterozygous for the *Xist* deletion who carry the knock-in solely on the Xi. The *AMOTL1*, *NOV*, and *NR2E1* MaxiP constructs showed similar levels of *HPRT* DNA methylation on the Xi (∼70%) but slightly different levels of promoter DNA methylation on the Xi ([Figure 2B](#fig2){ref-type="fig"}). DNA methylation levels at *PITX2* and *NGFR* were strikingly different from those at the other MaxiP constructs.

![DNA methylation analysis of flanking *HPRT* and *Phf6* genes reveals skewing of XCI and differential susceptibility of MaxiP constructs to DNA methylation on the Xi. (A) Spearman's correlation analysis between *Phf6* and the MaxiP DNA methylation levels showed no significant correlations. *AMOTL1*, *r* = 0.2532, *P* = 0.5206; *NGFR*, *r* = 0.1482, *P* = 0.7825; *NOV*, *r* = 0.2270, *P* = 0.5821; *NR2E1*, *r* = 0.4633, *P* = 0.0953; *PITX2*-CpG46, *r* = 0.2635, *P* = 0.5364. (B) Spearman's correlation analysis between *HPRT* and the MaxiP DNA methylation levels showed significant correlations, but differential capacity for DNA methylation was also observed. *AMOTL1*, *r* = 0.8869, *P* = 0.0011; *NGFR*, *r* = 0.8285, *P* = 0.0083; *NOV*, *r* = 0.7439, *P* = 0.0174; *NR2E1*, *r* = 0.6864, *P* = 0047; *PITX2*-CpG46, *r* = 0.9581, *P* = 0.0011. *Xist^1lox^* females (triangles) carrying different MaxiP constructs on the Xi showed different levels of DNA methylation, for which homozygous mice showed intermediate DNA methylation (open circles). Each circle or triangle indicates DNA methylation levels from an individual mouse.](1281fig2){#fig2}

*PITX2* (CpG island 46) showed a much lower range of DNA methylation when compared to DNA methylation of *AMOTL1*, *NOV*, and *NR2E1*, and DNA hypermethylation of *HPRT* indicates that the low level of female DNA methylation at *PITX2* is not attributable to skewing of XCI but to its intrinsic resistance to accumulate DNA methylation ([Figure 2B](#fig2){ref-type="fig"}). In contrast, the *NGFR* MaxiP construct showed a lower *HPRT* DNA methylation range (13--33%) compared to the other MaxiP constructs, suggesting that the capacity of *HPRT* to accumulate DNA methylation is altered in this construct. We also designed a DNA methylation assay ∼720 bp downstream of the start codon in the *lacZ* reporter, which showed similar DNA methylation levels on the Xi for all constructs except the *NGFR* BAC ([Figure S1](http://www.genetics.org/cgi/data/genetics.112.143743/DC1/2)). The *NGFR* BAC showed lower levels of *HPRT* and *lacZ* DNA methylation on the Xi than expected (*HPRT* average 41%, outlier; *lacZ* average 56%), suggesting the region is subject to substantial influence from the genomic context. Therefore, *PITX2* showed the largest decrease in capacity to accumulate promoter DNA methylation and the *NGFR* BAC showed an impact on *HPRT* DNA methylation. To understand the *cis*-modulatory effects of the integrated DNA, we explored the *PITX2* and *NGFR* BACs in more detail.

*PITX2* is DNA hypermethylated at transcription start sites as well as intragenic and intergenic CpG islands in females {#s11}
-----------------------------------------------------------------------------------------------------------------------

CpG island 46 on the *PITX2* BAC is not annotated as the start of the *PITX2* transcript, so we analyzed the DNA methylation levels at eight additional locations on the BAC including exon 1 and intron 2 (non-CpG island), three internal CpG islands, the promoter CpG island of the annotated alternative isoform, and two intergenic CpG islands ([Figure 3](#fig3){ref-type="fig"}). Although the first exon does not contain a CpG island, it still showed significantly higher DNA methylation in females than in males (*P* = 0.0084; [Figure 3](#fig3){ref-type="fig"}). In fact, all the locations tested in *PITX2* generally showed DNA hypermethylation in females compared to males, including the CpG island at the alternative promoter and the intergenic CpG islands. Although our DNA methylation assays are located in the gene body of *PITX2*, chromatin modifications associated with promoters were found to overlap the assays in intron 2 and CpG islands 46 and 196 ([Figure 3](#fig3){ref-type="fig"}) ([@bib13]), suggesting *PITX2* has additional internal promoters. Intergenic CpG islands 59 and 29 show no or very weak chromatin modifications associated with promoters or enhancers, yet both CpG islands showed female-specific DNA hypermethylation ([Figure 3](#fig3){ref-type="fig"}). Similarly, analysis of an intergenic and an intragenic CpG island on the *NR2E1* BAC demonstrated female-specific DNA hypermethylation (data not shown). Interestingly, *lacZ* showed a clear difference in DNA methylation levels between males and females ([Figure 3](#fig3){ref-type="fig"}), in agreement with the DNA methylation status of multiple sites in *PITX2*. Thus, while CpG islands 18 and 46 showed lower female DNA methylation (average 14%), because other locations in the gene consistently showed DNA hypermethylation in females at levels consistent with XCI, we conclude that *PITX2* is likely subject to XCI based on DNA methylation. Consistent with published data ([@bib42]), our assessment of male and female blood and lymphoblast lines suggests that in humans the promoter CpG island 196 is always unmethylated while other sites show variable DNA methylation that is not sex specific (data not shown), with the exception of CpG island 29, which appears to be DNA methylated in all tissues except sperm.

![DNA methylation analyses of multiple regions in the *PITX2* BAC construct show varying extents of DNA hypermethylation in females. DNA methylation assays were designed in the gene body, within or outside of CpG islands, as well as in the intergenic CpG islands. The corresponding locations of the DNA methylation assays are shown with dashed lines to the sites on the construct. The gene is depicted with three transcript isoforms ([@bib12]) and the BAC (RP11-268I1) is shown below. Location of the *lacZ* insertion is indicated with a downward arrow. The promoter marks are based on the ENCODE study on chromatin states by [@bib13]. Circles, DNA methylation of the individual sample; bar in the center of the error bars, average DNA methylation for the strain; error bars, ±1 standard deviation between mice for the strain. Significance is tested using a Mann--Whitney *t*-test. n.t., not tested due to limited male samples.](1281fig3){#fig3}

A truncated gene on the *NGFR* BAC construct partially escapes from XCI {#s12}
-----------------------------------------------------------------------

A distinguishing characteristic of the *NGFR* construct from the other MaxiP constructs was the presence of a truncated gene at the end of the BAC that is adjacent to the *HPRT*/*Hprt* locus ([Figure 4A](#fig4){ref-type="fig"}). The *PHB* gene is truncated within the 3′-UTR ∼200 bp from the end of the gene, and we hypothesized that *PHB* escaped from XCI and that the run-on transcription from *PHB* through the *HPRT*/*Hprt* locus positioned ∼2.5 kb downstream could be the cause of the reduced *HPRT* DNA methylation on the Xi. We therefore examined the transcription levels of *PHB* and the intergenic region between *PHB* and *HPRT*/*Hprt* in males and in females with and without the *Xist* deletion ([Figure 4B](#fig4){ref-type="fig"}). By qPCR, we showed that *PHB* was not a highly expressed gene relative to *Pgk1*, but was expressed from the Xi in females heterozygous for the *Xist* deletion at levels up to 30% of the level of expression observed in males ([Figure 4B](#fig4){ref-type="fig"}), while females with random XCI showed a level of *PHB* expression close to 60% of that in males. Variability was observed in *PHB* expression levels from the Xi between females, perhaps reflecting the variable escape from XCI previously described for X-linked genes ([@bib5]). However, while the expression level at ∼1.4 kb downstream of the truncated *PHB* gene in the intergenic region was essentially the same as at the 3′-UTR of *PHB* ([Figure 4B](#fig4){ref-type="fig"}), this transcription had ceased by ∼250 bp upstream of *HPRT*/*Hprt*, indicating that there is no substantial run-on transcription through the *HPRT*/*Hprt* locus. In addition, analysis of *HPRT* expression showed that *HPRT*/*Hprt* remained inactivated on the Xi despite its lower level of DNA methylation and proximity to a gene escaping from XCI. In agreement with the *PHB* expression analysis, the promoter of *PHB* has an island of intermediate CpG density (GC% = 52.9, observed/expected CpG = 0.57, length = 1823 bp) that showed relatively low DNA methylation in females with the *Xist* deletion, but the *PHB* DNA methylation level on the Xi was still distinct from the level of DNA methylation on the Xa in males ([Figure 4C](#fig4){ref-type="fig"}). Overall, it appears that *PHB* partially escapes from XCI; however, run-on transcription through *HPRT*/*Hprt* is not the cause of altered *HPRT* DNA methylation capacity on the Xi.

![*PHB* on the *NGFR* BAC escapes from XCI. (A) Structure of the *NGFR* MaxiP construct. *PHB* is truncated in the 3′-UTR on the BAC, located ∼2.5 kb from the *HPRT*/*Hprt* locus. Gray and green bars below the MaxiP indicate the locations of the expression and DNA methylation assays, respectively. Internal exons are not shown to scale. (B) Expression of *PHB*, the intergenic region between *PHB* and *HPRT*/*Hprt*, and *HPRT*/*Hprt* (exon 1), normalized to *Pgk1*. DNA from a mouse targeted at *Hprt* with BACs for *MKI67* (Ple131) and *NR2E1* (Ple142) served as negative controls (−) since they lack the *PHB* gene. The *x*-axis indicates whether *PHB* was present only on the Xi or on the Xa in a given mouse, or on either X chromosome (Xa Xi), as in the case for females with random XCI. Error bars indicate ±1 standard deviation between two qPCR runs. (C) DNA methylation of *PHB* promoter in ear notches of mice carrying the *NGFR* MaxiP on the Xi, either the Xa or the Xi, or the Xa. Error bars indicate ±1 standard deviation between mice for the strain.](1281fig4){#fig4}

MiniP constructs are generally subject to XCI {#s13}
---------------------------------------------

Since our MaxiP results agreed with previous reports that DNA methylation is an accurate marker for XCI status ([@bib20]; [@bib47]), we analyzed promoter DNA methylation of the MiniP constructs to predict their XCI statuses. Heterozygous females overall showed significantly higher DNA methylation levels at promoter CpG islands compared to males (female average, 45%; male average, 12%; *P* \< 0.0001). To determine whether there were MiniP promoters that might escape XCI, we analyzed the DNA methylation levels of the constructs separately. DNA methylation levels were analyzed at 46 island-containing MiniP constructs, which originated from 23 human genes. For MiniP constructs that were generated from the same gene and thus shared the same core promoter sequence, the same CpGs were examined for DNA methylation levels. Almost all MiniP constructs showed promoter DNA hypermethylation in females compared to males, with female and male averages of 44% and 4%, respectively, with the outliers removed in the analysis ([Figure 5A](#fig5){ref-type="fig"}). Of the Pleiades constructs that were also examined for expression in the ear notch samples, excluding the outliers, all showed female-specific DNA hypermethylation independent of whether the transgenes displayed expression ([Figure S2](http://www.genetics.org/cgi/data/genetics.112.143743/DC1/3)). For three constructs we observed DNA methylation levels \<2 standard deviations below the average in a single female, although still \>2 standard deviations above the average in males. These females thus might represent a gene with variable inactivation between mice; however, identification of variable escapees is confounded by skewing of XCI that could result in high standard deviations in DNA methylation levels among females of the same strain. The low DNA methylation level in single females for the three constructs was likely attributable to skewing of XCI, since *HPRT* DNA methylation levels were also lower (8--27%) in these females. Therefore, for a transgene to be qualified as a potential escapee, we required consistent low promoter DNA methylation in multiple heterozygous female mice. Since our MiniP constructs generally showed elevated average DNA methylation in females compared to males, we concluded that none of the MiniP constructs appeared to escape XCI. Promoter DNA hypermethylation was observed in males for the MiniP constructs derived from genes *CARTPT*, *GPX3*, *ICMT*, *OXT*, and *POGZ*, but did not appear to correlate with transgene silencing ([Table S1](http://www.genetics.org/cgi/data/genetics.112.143743/DC1/7) and [Figure S2](http://www.genetics.org/cgi/data/genetics.112.143743/DC1/3)). It is unknown what DNA sequences in these elements generate exceptions to the DNA methylation patterns observed for the majority of the MiniPs, but interestingly for one of these (*CARTPT*) the endogenous island shows DNA hypermethylation at the endogenous promoter. In general, we analyzed fewer mice per construct for the MiniPs, but overall MiniP constructs showed higher levels of DNA methylation compared to the MaxiP constructs (average 45% and 33%, respectively, *P* \< 0.0001), perhaps reflecting a closer association of the MiniPs with X-linked *cis*-acting elements or a protective influence of sequences within the large BAC constructs. DNA methylation levels at *HPRT* and *Phf6* were not significantly different between MiniPs and MaxiPs ([Figure 5, B and C](#fig5){ref-type="fig"}).

![Promoter DNA methylation of the MiniP constructs is reflective of XCI. (A) DNA methylation levels of individual MiniP constructs. Constructs with *lacZ*, EGFP, and EGFP/cre as the reporter are colored in blue, green, and black, respectively. Circles, DNA methylation of the individual sample; bar in the center of the error bars, average DNA methylation for the strain; error bars, ±1 standard deviation between mice for the strain; shaded regions, 2 standard deviations from the average DNA methylation level with outlier strains removed. Outliers are marked with asterisks (\*). Female outlier: *POGZ* (Ple167). Male outliers: *CARTPT* (Ple20, Ple21), *GPX3* (Ple97), *ICMT* (Ple123), *OXT* (Ple152, Ple153), and *POGZ* (Ple167, Ple170). Modified *Z*-scores \>3.5 in absolute values were marked as outliers ([@bib25]). (B and C) *Phf6* promoter (B) and *HPRT* promoter (C) both showed a significant difference in DNA methylation levels between males and females. A Mann--Whitney *t*-test was used to test for significance. Boxplot whiskers are 5th--95th percentiles. Circles, the average DNA methylation levels of each strain.](1281fig5){#fig5}

*lacZ* reporter consistently reflects DNA methylation pattern of CpG island promoters {#s14}
-------------------------------------------------------------------------------------

*lacZ* DNA methylation resembled the DNA methylation pattern of the promoter region in *PITX2*, leading us to test the utility of *lacZ* DNA methylation to predict XCI status. Similar to CpG island promoters, female mice showed significantly higher *lacZ* DNA methylation than males (*P* \< 0.0001), even though males did have substantial DNA methylation (male and female average DNA methylation levels of 26% and 49%, respectively). Mice with an autosomal *lacZ* showed no significant difference in DNA methylation levels between males and females ([Figure S3](http://www.genetics.org/cgi/data/genetics.112.143743/DC1/4)), indicating that the difference in the DNA methylation levels of the X-linked *lacZ* between the sexes is likely a consequence of the epigenetic regulation of XCI. The lower level of male (Xa) DNA methylation for X-linked *lacZ* may reflect the previously reported permissive nature of the *Hprt* integration sites ([@bib4]; [@bib11]). Although *lacZ* showed overall higher DNA methylation than the CpG island promoters (male *P* \< 0.0001; female *P* = 0.0029), *lacZ* DNA methylation showed a significant correlation with DNA methylation of the promoter island in females ([Figure 6A](#fig6){ref-type="fig"}). Since constructs with and without CpG islands in the promoter both showed a significant difference between female and male *lacZ* DNA methylation levels (*P* \< 0.0001 and *P* = 0.0008, respectively), we used *lacZ* DNA methylation as a surrogate for promoter DNA methylation and screened additional Pleiades constructs for which there was no assay for promoter DNA methylation ([Figure 6B](#fig6){ref-type="fig"}). Consistent with the lack of *lacZ* expression in X*Xist^1lox^*/X*^MAOA^* and X*Xist^1lox^*/X*^NR2F2^* mice ([Figure 1B](#fig1){ref-type="fig"}), *MAOA* and *NR2F2* showed female-specific *lacZ* DNA hypermethylation ([Figure 6B](#fig6){ref-type="fig"}), further supporting the usage of this locus as a surrogate to determine XCI status. However, compared to promoter DNA methylation ([Figures 1C](#fig1){ref-type="fig"} and [5A](#fig5){ref-type="fig"}), males more often showed DNA hypermethylation of the *lacZ* reporter ([Figure 6B](#fig6){ref-type="fig"} and [Figure S4](http://www.genetics.org/cgi/data/genetics.112.143743/DC1/5)). Using the criteria of nonoverlapping standard deviations of DNA methylation between the sexes and a male average DNA methylation level \<2 standard deviations of the female average of all strains, we excluded seven strains, including two (*DCX* Ple53 and *VIP* Ple250) for which the single male analyzed showed higher DNA methylation than the female average. Thus, we predict an additional 11 constructs subject to XCI based on *lacZ* DNA methylation.

![*lacZ* DNA methylation can be used as a surrogate for promoter DNA methylation. (A) Spearman's correlation between *lacZ* and promoter DNA methylation levels in females. Circles, DNA methylation levels from an individual mouse. (B) *lacZ* DNA methylation levels of the Pleiades constructs that do not have a DNA methylation assay in the promoter region due to difficulty in assay design, assay failure, or absence of a CpG island. All constructs shown here have *lacZ* as the reporter on the X chromosome. Circles, DNA methylation levels from an individual mouse; bar in the center of the error bars, average DNA methylation for the strain; error bars, ±1 standard deviation between mice for the strain; shaded regions are the 2 standard deviations from the female average DNA methylation level with the outlier strains removed. Outliers are marked with asterisks (\*). Female outlier: *VIP* (Ple250).](1281fig6){#fig6}

Discussion {#s15}
==========

Arguably the most dramatic example of *cis*-regulation in the mammalian genome is silencing of one X chromosome in females. However, the *cis*-acting elements involved in spreading heterochromatin along the ∼155-Mb chromosome from the initiating elements in the X inactivation center remain unknown. Having 74 different human transgenes integrated into the mouse X chromosome presented us with an opportunity to assess *cis*-regulation of ∼1.5 Mb of DNA at the identical genomic location. Analysis of female mice heterozygous for an *Xist* deletion causing nonrandom inactivation of the knock-in--bearing X chromosome provided clear evidence for XCI of four of the knock-ins ([Figure 1](#fig1){ref-type="fig"}). As a more rapid approach to assess the XCI status of multiple transgenes, we used DNA methylation as a surrogate measure of inactivation, since promoter DNA hypermethylation in females relative to males can be attributed to DNA methylation of the Xi and thus reflects inactivation of the gene ([@bib53]; [@bib9]). We demonstrated that in addition to such DNA hypermethylation for the genes subject to XCI, the escaping *PHB* gene in our system exhibited low promoter DNA methylation in both sexes, validating the usage of DNA methylation to detect genes subject to, and escaping from, XCI. As the determination of whether a gene is subject to XCI could be confounded by skewing of XCI and there can be variability between females for whether a gene escapes XCI ([@bib5]), we included an assessment of *HPRT* DNA methylation to detect samples with skewed XCI and we required consistently high promoter DNA methylation in multiple females to call a gene subject to XCI. Overall, 92% of the constructs analyzed showed DNA hypermethylation of the human promoters in female mice compared to males ([Figures 1C](#fig1){ref-type="fig"} and [5A](#fig5){ref-type="fig"}), indicative of XCI of the knock-in gene.

Our goal in determining the XCI status of the 74 knock-in constructs was to characterize *cis*-acting elements involved in the spread of epigenetic silencing. In 1983 Gartler and Riggs proposed waystations as elements enriched upon the X chromosome that aid in spreading the silencing signal along the chromosome, based on the limited spread of XCI into autosomes that is seen for X;autosome translocations ([@bib16]). Because MiniP constructs are small transgenes, it is not surprising that all were shown to be subject to XCI, since they are in close proximity to X-linked DNA and putative waystations. Indeed, the majority of previous studies on X-linked transgenes have reported silencing of the examined transgenes on the Xi. However, the ∼187-kb chicken transferrin transgene is one of the few exceptions that consistently escaped from XCI ([@bib19], [@bib20]). As the MaxiP constructs were of a similar size (120--195 kb), we anticipated that the MaxiPs originating from autosomes would have a high probability to lack waystations and escape from XCI. However, our results demonstrated that mouse XCI is consistently capable of inactivating foreign transgenes up to 195 kb. Thus, escape from XCI of the chicken transgene may reflect integration into a waystation-poor region relative to *Hprt*. In addition, however, there is now evidence for a different type of *cis*-regulatory element. Recently four different integrations of a *Kdm5c* BAC recapitulated both escape from XCI for *Kdm5c* and silencing for the flanking *Tspyl2* and *Iqsec2* genes, strongly supporting the existence of a *cis*-acting element on the BAC that controlled escape from XCI ([@bib27]). Therefore, we hypothesize that there are both waystations and escape elements regulating the spread of XCI.

Escape elements are presumably outside the promoter as none of the 46 MiniPs examined in this study nor the majority of previously examined transgenes escape from XCI. We determined that the *PHB* gene escapes from XCI, and as waystations are reduced in abundance on autosomes and *NGFR* is subject to XCI while being farther from the mouse X-linked DNA than *PHB* (see [Table S2](http://www.genetics.org/cgi/data/genetics.112.143743/DC1/8)), we conclude that the *PHB* region likely carries an escape element to escape from XCI. The observed reduction of *HPRT* DNA methylation to 41% on the Xi when adjacent to *PHB*, from an average of 70% DNA methylation on the Xi for other MaxiP constructs, suggests that the dominant escape element also influenced the *HPRT* locus. The *PHB* gene is truncated in the 3′-UTR of the gene; however, we demonstrated that transcription ceased before the *HPRT* promoter, and since the promoter, splice junctions, and coding sequences are intact, we do not believe that this truncation *per se* affects either the propensity for *PHB* to escape from XCI or the loss of DNA methylation at *HPRT*. Interestingly, the reduced DNA methylation at *HPRT* was still sufficient to maintain XCI, while the 15% DNA methylation of *PHB* was insufficient for silencing, although there was not full expression from the Xi relative to the Xa. Given that we observed only one such escape element in 47 genes and 1.5 Mb of DNA, our data support the existence of relatively rare dominant escape elements. As escape from XCI is frequent in X;autosome translocations \[∼30% (reviewed in [@bib50])\], it is likely that, as previously proposed, such escape more generally reflects a lack of waystations rather than the presence of escape elements. We therefore decided to examine the large MaxiP constructs to determine whether there was evidence for particular elements that might be functioning as waystations.

Waystations have been proposed to be repetitive elements, and we calculated the base coverage in the MaxiP for several repeat elements previously positively or negatively correlated with genes escaping XCI: LINE-1, LINE-2, and Alu ([@bib2]; [@bib6]; [@bib45]). Only Ple142 (*NR2E1*) and Ple126 (*LCT*) appeared to possess an environment that resembles the genomic context of escapees based on LINE-1, LINE-2, and Alu base coverage on the BAC ([Figure S5](http://www.genetics.org/cgi/data/genetics.112.143743/DC1/6)). However, promoter DNA hypermethylation of *NR2E1* and *LCT* in females suggests that the genes were subject to XCI ([Figure 1C](#fig1){ref-type="fig"}). Although only eight BACs were examined, our analysis of LINEs and Alu content suggests that these three repetitive elements are insufficient to determine whether a gene is subject to XCI and that additional repeats or a combination of other factors may be required to provide a better prediction of the XCI status.

In addition to our search for *cis*-acting regulatory elements, our analysis of the Pleiades human knock-in constructs into the X-linked *Hprt* docking site revealed several other insights into the relationship of DNA methylation with XCI. First, we demonstrated that constructs have an intrinsic differential capacity for DNA methylation. Through analyzing MaxiP DNA methylation of female mice with complete nonrandom XCI due to an *Xist* deletion, we showed that different MaxiP constructs could accumulate DNA methylation at the promoters to different extents on the Xi ([Figure 2B](#fig2){ref-type="fig"}). However, the *HPRT* promoter and the *lacZ* reporter, which are shared among the MaxiP constructs, generally exhibited similar levels of DNA methylation ([Figure S1](http://www.genetics.org/cgi/data/genetics.112.143743/DC1/2)), suggesting that the capacity to accumulate DNA methylation is a characteristic of the DNA sequence. Intriguingly, there may be differences between hemizygous and heterozygous or between homozygous and heterozygous states, as the observed promoter DNA methylation levels in females with the *Xist* deletion tend to be lower than the expected level of DNA methylation on the Xi based on the assumption that the DNA methylation on the Xa is equivalent between males and females.

Second, the differential female:male DNA methylation observed on the X is found beyond CpG-island promoters. Xa-specific DNA methylation has been reported in gene bodies ([@bib24]). Our results demonstrated that the influence of XCI on DNA methylation of transgenes applies not only to promoters, but also to gene body and intergenic CpG islands, since all analyzed locations on the *PITX2* BAC showed female-specific DNA hypermethylation that was not observed on the endogenous human chromosome ([Figure 3](#fig3){ref-type="fig"}), including regions such as CpG island 29 for which there is no evidence for promoter activity ([@bib13]) or overlap with conserved transcription factor binding sites (TRANSFAC Biobase, <http://www.gene-regulation.com/pub/databases.html>). Therefore, it is possible that the default state of CpG islands on the X chromosome is to acquire DNA methylation on the Xi and this is independent of whether the transgenes were expressed ([Figure S2](http://www.genetics.org/cgi/data/genetics.112.143743/DC1/3)), consistent with the majority of the CpG islands being DNA hypermethylated on the Xi ([@bib9]; [@bib37]), and tissue-specific genes such as the human X-linked androgen receptor showing female-specific DNA hypermethylation independent of expression ([@bib1]).

The recognition of CpG islands for DNA methylation on the Xi could explain the DNA hypermethylation in females compared to males on the X chromosome for the *lacZ* reporter ([Figure 6](#fig6){ref-type="fig"}), which is essentially an ∼3000-bp CpG island. Promoter-less artificial CpG islands inserted into the 3′-UTR of an autosomal and an X-linked gene have been shown to recruit the unmethylated CpG-binding protein Cfp1 and the promoter histone mark H3K4me3 even in the absence of RNA polymerase II binding ([@bib43]), although the X-linked locus has some DNA methylation presumably due to XCI. The ability of CpG-rich sequences to acquire characteristics of promoters further supports using *lacZ* DNA methylation as a surrogate for promoter DNA methylation to predict whether transgenes are subject to XCI. However, *lacZ* DNA methylation is not as robust a predictor of XCI status as the promoter DNA methylation since a higher frequency of males with DNA hypermethylation was observed.

A third insight was the unexpected observation that the differential female:male DNA methylation may reflect not only gain of DNA methylation on the Xi, but also protection from DNA methylation on the Xa. In general, promoter CpG islands are unmethylated on the autosomes; however, ∼4% are reported to show DNA methylation, often with variability between tissues ([@bib38]). Four of the 35 autosomal CpG islands analyzed (*CARTPT*, *OXT*, *THY1*, and *PITX2*: CpG island 29) showed an average of \>20% DNA methylation in male and female cell lines and/or blood samples (data not shown; [@bib42]). However, when *THY1* and the *PITX2* BAC were present on the X chromosome, they became unmethylated on the Xa; this loss of DNA methylation on the Xa compared to the autosomal locus was also observed for a non-CpG island site (exon 1 of *PITX2*) and the *lacZ* reporter. In the knock-in mice, *CARTPT* continued to show DNA methylation; however, *OXT* dropped from 60% DNA methylation on the autosome to only 20% DNA methylation in males, again showing decreased DNA methylation in males. In general we observed a dominant regulation of XCI on promoter DNA methylation, with female-specific gain of DNA hypermethylation and in several cases a male-specific loss of DNA methylation.

Overall, our analysis of the Pleiades human promoter constructs integrated into the mouse *Hprt* locus identified 1 of 47 genes in \>1.5 Mb of human DNA that escaped inactivation. We propose that there is a dominant *cis*-acting escape element near the *PHB* gene that allows it to escape from XCI in an otherwise inactivated region on the X chromosome. This element exerts an influence on the DNA methylation of the flanking *HPRT* locus, but does not lower DNA methylation to a level that allows expression from the Xi. That eight autosomal BACs ranging in size from 120 to 195 kb contained a gene subject to XCI when integrated at the *Hprt* site suggests that waystations are likely able to act over a distance of at least 100 kb, in the absence of dominantly acting escape elements. Further analyses of BAC integrations at the *Hprt* locus will be useful to identify the nature of these escape elements as well as the boundaries that prevent their influence on adjacent genes.
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